Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 4:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–69 of 69 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Emtricitabine/tenofovir alafenamide (F/TAF) Clear all

Conditions: HIV-1-Infection
Interventions: ISL/LEN, Antiretroviral Combinations; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 49
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 41 more

Conditions: Healthy Volunteers
Interventions: emtricitabine 200 mg/tenofovir alafenamide 25mg; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 59 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: HIV-1 Infection
Interventions: BIC, F/TAF, DTG, BIC Placebo, DTG Placebo, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 21
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 15 more

Conditions: HIV-1 Infection
Interventions: E/C/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 3
States / cities: Ft. Pierce, Florida • Orlando, Florida • West Palm Beach, Florida

Conditions: HIV Infections
Interventions: Lenacapavir Injection, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Emtricitabine/tenofovir alafenamide (F/TAF), Cabotegravir (CAB), Lenacapavir Tablet; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Timeline: 2026 – 2029
U.S. locations: 39
States / cities: Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 26 more

Conditions: HIV-1-infection
Interventions: B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Ft. Pierce, Florida • West Palm Beach, Florida

Conditions: HIV-1, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions: E/C/F/TAF, DRV, Baseline DRV- containing ARV regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 56
States / cities: Phoenix, Arizona • Beverly Hills, California • Hayward, California + 43 more

Conditions: HIV-1-infection
Interventions: GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 45
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 40 more

Conditions: HIV-1-infection
Interventions: Bictegravir, Lenacapavir, B/F/TAF, Placebo to match B/F/TAF, Placebo to match BIC/LEN; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 577 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 51
States / cities: Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 43 more

Conditions: HIV-1 Infection
Interventions: DTG, F/TAF, B/F/TAF, DTG Placebo, F/TAF Placebo, B/F/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 657 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 74
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 53 more

Conditions: HIV, HIV Infections
Interventions: E/C/F/TAF, E/C/F/TDF, E/C/F/TDF Placebo, E/C/F/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 872 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 78
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 55 more

Conditions: HIV
Interventions: FTC/TAF; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 14 Years to 100 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV I Infection
Interventions: Dolutegravir / Lamivudine Pill, Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill; Drug
Lead sponsor: Charlotte-Paige Rolle, MD; Other
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: HIV -1 Infection, HIV (Human Immunodeficiency Virus), HIV, HIV 1 Infection
Interventions: Bictegravir, emtricitabine, and tenofovir alafenamide; Drug
Lead sponsor: CAN Community Health; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: Clearwater, Florida • Ft. Pierce, Florida • Jacksonville, Florida + 6 more

Conditions: HIV-1-infection
Interventions: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC); Drug
Lead sponsor: The Crofoot Research Center, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV-1-infection
Interventions: Bavtavirine, B/F/TAF, Standard of Care (Substudy 01), GS-1720, Standard of Care (Substudy 02), GS-6212, Standard of Care (Substudy 03); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 38
States / cities: Long Beach, California • Los Angeles, California • San Francisco, California + 14 more

Conditions: HIV-1 Infection
Interventions: B/F/TAF (Adult Strength), B/F/TAF (Low Dose), B/F/TAF (TOS); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 10
States / cities: Washington D.C., District of Columbia • Ft. Pierce, Florida • Gainesville, Florida + 7 more

Conditions: Immunodeficiency Virus Type 1, Human
Interventions: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC, DRV/COBI FDC, FTC/TDF FDC, D/C/F/TAF FDC - Matching Placebo, FTC/TDF FDC Matching Placebo, DRV/COBI FDC Matching Placebo; Drug
Lead sponsor: Janssen Sciences Ireland UC; Industry
Eligibility: 18 Years and older
Enrollment: 725 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 29
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 26 more

Conditions: Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions: E/C/F/TAF, E/C/F/TAF (Low Dose); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 5
States / cities: Long Beach, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more

Conditions: Acquired Immunodeficiency Syndrome, HIV Infections
Interventions: E/C/F/TDF, ATV, RTV, FTC/TDF, E/C/F/TDF Placebo, ATV Placebo, RTV Placebo, FTC/TDF Placebo, E/C/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 583 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 41
States / cities: Los Angeles, California • Sacramento, California • Washington D.C., District of Columbia + 31 more

Conditions: HIV-1-infection
Interventions: Oral Lenacapavir, F/TAF, Subcutaneous Lenacapavir, TAF, BIC, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 49
States / cities: Phoenix, Arizona • Los Angeles, California • Palm Springs, California + 40 more

Search by objective public record fields.

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

The Cellular Pharmacology of F-TAF in Dried Blood Spots

Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

Emtricitabine/Tenofovir Alafenamide as Salvage ART

Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF

REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE

Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)

Study of Novel Antiretrovirals in Participants With HIV-1

Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1

A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects

Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV